The identified deviation concerns the content parameter of the active substance topotecan; administering the medicine with an increased amount of topotecan compared to the declared dose may negatively affect treatment tolerance. Hematological toxic effects are dose‑dependent. Potential effects: hematological toxicity, complications of oncology treatment.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use Hycamtin with batch numbers BCUN2 and BCUN3; if you have these packs, return them to the pharmacy and consult a doctor or pharmacist.
The Chief Pharmaceutical Inspector prohibited placing Hycamtin batches BCUN2 and BCUN3 on the market throughout the country and granted the decision immediate enforceability; an explanatory procedure ...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related